MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Gilead Sciences Inc.

Fechado

SetorSaúde

107.23 -4.57

Visão Geral

Variação de preço das ações

24h

Atual

Mín

103.66

Máximo

112.82

Indicadores-chave

By Trading Economics

Rendimento

530M

1.8B

Vendas

29M

7.6B

P/E

Médio do Setor

294.868

63.778

EPS

1.9

Rendimento de Dividendos

2.82

Margem de lucro

23.557

Funcionários

17,600

EBITDA

-655M

3.1B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+2.57% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.82%

2.39%

Próximos Ganhos

24 de abr. de 2025

Próxima data de dividendos

26 de jun. de 2025

Próxima data de ex-dividendo

13 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

18B

140B

Abertura anterior

111.8

Fecho anterior

107.23

Sentimento de Notícias

By Acuity

33%

67%

83 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Gilead Sciences Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de fev. de 2025, 21:17 UTC

Ganhos

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

19 de dez. de 2024, 15:25 UTC

Grandes Movimentos do Mercado

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

19 de dez. de 2024, 13:38 UTC

Grandes Movimentos do Mercado

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

6 de nov. de 2024, 22:25 UTC

Ganhos

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

19 de mar. de 2025, 14:50 UTC

Principais Notícias

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 de fev. de 2025, 22:13 UTC

Conversa de Mercado
Ganhos

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 de fev. de 2025, 21:06 UTC

Ganhos

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Raises Dividend 2.6%>GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q HCV Products Sales >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q Adj EPS $1.90 >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q Rev $7.57B >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q EPS $1.42 >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q EPS $1.42 >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q Net $1.78B >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q Rev $7.6B >GILD

11 de fev. de 2025, 21:02 UTC

Ganhos

Gilead Sciences 4Q Adj EPS $1.90 >GILD

10 de jan. de 2025, 10:30 UTC

Principais Notícias

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

29 de dez. de 2024, 08:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

19 de dez. de 2024, 13:23 UTC

Grandes Movimentos do Mercado

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

7 de nov. de 2024, 16:23 UTC

Ganhos

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Comparação entre Pares

Variação de preço

Gilead Sciences Inc. Previsão

Preço-alvo

By TipRanks

2.57% parte superior

Previsão para 12 meses

Média 115.28 USD  2.57%

Máximo 140 USD

Mínimo 89 USD

Com base em 23 analistas de Wall Street que oferecem metas de preço de 12 meses para Gilead Sciences Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

23 ratings

17

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

106.0982 / 111.81Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

83 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.